Molecular profiling and precision medicine in rare gastrointestinal cancers within EURACAN in the SPECTA Arcagen study (EORTC-1843): too few patients with matched treatment in Europe

Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACAN

“…The Arcagen project, a subset of the SPECTA project of the EORTC enabled the collection of molecular data for 1032 patients with rare cancers. 10 , 40 Another project launched under the umbrella of EURACAN is the Tracking project, collecting the outcome of patients with rare molecular alterations ( https://euracan.eu/registries/tracking/ ). Since 2022, EURACAN has been working on the elaboration of unified Standard Operating Procedures to be shared and adopted with the aim to perform prospective and retrospective observational studies, including those relying on EURACAN registry (ies).…”

The promise of precision medicine: how biomarkers are shaping the future of cholangiocarcinoma treatment

“…One of the main challenges is access to testing and matched treatments for the identified alterations. A recent study by EORTC has highlighted this issue, showing that access to treatment remains challenging, especially in Europe ( 14 ). In this study, despite identifying a targetable alteration in around 35% of iCCAs, less than 10% were able to receive a tailored treatment for that alteration.…”